Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Gerber WK, Xie Y, Patel SA. Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors. JCO Precis Oncol. 2025 Mar; 9:e2400753.
-
Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, Ruggeri T, Laffaille M, Irving M, Coukos G, Lanitis E, Dunn SM. Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager. J Immunother Cancer. 2025 Mar 13; 13(3).
-
Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, Gundem G, Domenico D, Mitra S, Socci ND, Everett JK, Roche AM, Petrichenko A, Shah GL, Arcila ME, Borsu L, Park JH, Horwitz SM, Giralt SA, Dogan A, Leslie C, Papaemmanuil E, Bushman FD, Usmani SZ, Sadelain M, Mailankody S. CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53. N Engl J Med. 2025 Feb 06; 392(6):577-583.
-
Patel SA, Spiegel JY, Dahiya S. Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review. JAMA Oncol. 2025 Feb 01; 11(2):174-181.
-
Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona RI, Girgis S, Miao X, Uhlar CM, Chastain K, Garfall AL. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024 Dec 05; 144(23):2375-2388.
-
Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H, Tan CR, Hultcrantz M, Shah GL, Landau HJ, Chung DJ, Scordo M, Eren OC, Dogan A, Giralt SA, Park JH, Rivi?re I, Brentjens RJ, Smith EL, Wang X, Usmani SZ, Mailankody S. Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis. J Clin Oncol. 2025 Feb 10; 43(5):498-504.
-
Makwana B, Malode A, Khadke S, Patel V, Shah R, Patel M, Parikh A, Dani SS, Ganatra S. Cardiac Complications of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor?T Cell Therapy. Cardiol Clin. 2025 Feb; 43(1):151-167.
-
Hansen DK, Lu X, Puglianini OC, Sorensen S, Usmani SZ, Zhang E, Huo S, Zhang Y, Qureshi ZP, Jagannath S. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Front Immunol. 2024; 15:1408892.
-
Schett G, M?ller F, Taubmann J, Mackensen A, Wang W, Furie RA, Gold R, Haghikia A, Merkel PA, Caricchio R, D'Agostino MA, Locatelli F, June CH, Mougiakakos D. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024 Sep; 20(9):531-544.
-
Howard AJ, Concepcion I, Wang AX, Hamadeh IS, Hultcrantz M, Mailankody S, Tan C, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Chung DJ, Giralt S, Usmani SZ, Firestone RS. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies. Blood Adv. 2024 06 25; 8(12):3246-3253.